NCT07695142

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2026-08-07Est. Completion: 2028-12-30

Enrollment target: 275 participants

Locations

Fudan University Shanghai Cancer Center, Shanghai, China

Other microbiome trials you might be interested in

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine CancersPhase 1Recruiting

Small Cell Lung CancerLarge Cell Neuroendocrine Lung CarcinomaExtrapulmonary Neuroendocrine Carcinoma of Small Cell HistologyExtrapulmonary Neuroendocrine Carcinoma of Large Cell Histology

This study is open to adults with advanced small cell lung cancer and other neuroendocrine cancers. The study has 2 part…

Washington D.C., United StatesEst. completion Apr 26, 2030

View Trial →

DBC-664 in Adult Patients With Solid TumorsPhase 1Recruiting

Malignant Germ Cell TumorLung AdenocarcinomaGastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.